PT3114214T - Métodos de reprogramação melhorados e plataformas de cultura celular - Google Patents

Métodos de reprogramação melhorados e plataformas de cultura celular

Info

Publication number
PT3114214T
PT3114214T PT157577537T PT15757753T PT3114214T PT 3114214 T PT3114214 T PT 3114214T PT 157577537 T PT157577537 T PT 157577537T PT 15757753 T PT15757753 T PT 15757753T PT 3114214 T PT3114214 T PT 3114214T
Authority
PT
Portugal
Prior art keywords
cell culture
reprogramming methods
culture platforms
improved reprogramming
improved
Prior art date
Application number
PT157577537T
Other languages
English (en)
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of PT3114214T publication Critical patent/PT3114214T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0696Artificially induced pluripotent stem cells, e.g. iPS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/115Basic fibroblast growth factor (bFGF, FGF-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/15Transforming growth factor beta (TGF-β)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/235Leukemia inhibitory factor [LIF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/415Wnt; Frizzeled
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/72Transferases (EC 2.)
    • C12N2501/724Glycosyltransferases (EC 2.4.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/72Transferases (EC 2.)
    • C12N2501/727Kinases (EC 2.7.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT157577537T 2014-03-04 2015-03-04 Métodos de reprogramação melhorados e plataformas de cultura celular PT3114214T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461947979P 2014-03-04 2014-03-04

Publications (1)

Publication Number Publication Date
PT3114214T true PT3114214T (pt) 2024-01-03

Family

ID=54055848

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157577537T PT3114214T (pt) 2014-03-04 2015-03-04 Métodos de reprogramação melhorados e plataformas de cultura celular

Country Status (11)

Country Link
US (2) US11268069B2 (pt)
EP (3) EP3604499A1 (pt)
JP (6) JP6722108B2 (pt)
KR (3) KR102460549B1 (pt)
CN (1) CN106414721A (pt)
AU (2) AU2015227184B2 (pt)
CA (1) CA2941004A1 (pt)
ES (1) ES2966757T3 (pt)
PT (1) PT3114214T (pt)
SG (2) SG10201807292YA (pt)
WO (1) WO2015134652A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822638C (en) 2010-12-22 2021-02-16 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
AU2015227184B2 (en) * 2014-03-04 2021-05-20 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
JP6800859B2 (ja) 2015-01-26 2020-12-16 フェイト セラピューティクス,インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
EP3324982A4 (en) 2015-07-21 2019-01-09 The Children's Medical Center Corporation HEMATOPOIETIC STEM CELLS EXPRESSING PD-L1 AND USES
JP7263005B2 (ja) 2015-10-16 2023-04-24 フェイト セラピューティクス,インコーポレイテッド 基底状態の多能性の誘導及び維持に関するプラットフォーム
JP6979946B2 (ja) * 2015-10-21 2021-12-15 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation ヒト内耳感覚上皮および感覚ニューロンを生成する方法
AU2016348342B2 (en) 2015-11-04 2023-07-06 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
PT3371314T (pt) 2015-11-04 2023-08-31 Fate Therapeutics Inc Modificação genómica de células pluripotentes
KR20180105670A (ko) * 2016-01-12 2018-09-28 론자 워커스빌 아이엔씨. 벡터-프리 유도만능 줄기세포를 생성시키기 위한 방법 및 벡터
KR102537361B1 (ko) * 2016-12-27 2023-05-26 스미또모 가가꾸 가부시키가이샤 인공 다능성 줄기 세포의 평가 방법 및 선발 방법, 그리고 인공 다능성 줄기 세포의 제조 방법
CN106754729B (zh) * 2016-12-31 2020-03-17 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
KR20200055801A (ko) * 2017-10-11 2020-05-21 페이트 세러퓨틱스, 인코포레이티드 시간적 및 일시적 플라스미드 벡터 발현 시스템을 사용한 세포 재프로그래밍
MX2020005701A (es) 2017-12-22 2020-10-28 Fate Therapeutics Inc Células efectoras inmunitarias potenciadas y usos de las mismas.
US20200339958A1 (en) * 2017-12-28 2020-10-29 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Generation of induced pluripotent cells by crispr activation
US20210010030A1 (en) * 2018-03-22 2021-01-14 Nserm (Institut National De La Santé Et De La Recherche Médicale) Method for reprogramming somatic cells
CN109679918A (zh) * 2018-12-25 2019-04-26 合肥中科干细胞再生医学有限公司 一种便捷的人诱导性多能干细胞的制备方法
JP7273141B2 (ja) * 2019-03-29 2023-05-12 富士フイルム株式会社 特定細胞に分化する能力を有する多能性幹細胞の製造方法およびその応用
CN110564673A (zh) * 2019-09-26 2019-12-13 广东工业大学 一种干细胞培养液及其应用
KR20220113349A (ko) * 2019-12-11 2022-08-12 리페아론 게엠베하 생물반응기의 현탁액에서 줄기세포의 확장
CN116438295A (zh) * 2020-06-22 2023-07-14 生命技术公司 培养多能细胞悬浮液的方法和组合物
EP4222249A1 (en) * 2020-10-02 2023-08-09 Fate Therapeutics, Inc. Improved reprogramming, maintenance and preservation for induced pluripotent stem cells
WO2023192876A1 (en) * 2022-03-28 2023-10-05 Reilly Steve E Composition to increase cellular longevity
WO2024078119A1 (en) * 2022-10-12 2024-04-18 Peking University Methods for chemical reprogramming and pluripotent stem cells

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
WO1993005021A1 (en) 1991-09-06 1993-03-18 Yoshitomi Pharmaceutical Industries, Ltd. 4-amino(alkyl)cyclohexane-1-carboxamide compound and use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
EP0710283A4 (en) 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
NZ513800A (en) 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
ES2321462T3 (es) 1997-05-07 2009-06-05 Pharma Mar, S.A. Uso de aplidina para el tratamiento de enfermedades cardiovasculares.
DE69839444D1 (de) 1997-06-13 2008-06-19 Ludwig Inst Cancer Res Smad 6 und dessen anwendungen
PT993439E (pt) 1997-07-01 2004-12-31 Warner Lambert Co Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
US6800790B2 (en) 1998-07-24 2004-10-05 Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the TFG-β family of growth factors
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
DE69924641D1 (de) 1999-01-07 2005-05-12 Warner Lambert Company Llc Mor Behandlung von asthma anhand von mek-inhibitoren
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
AU5250400A (en) 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
WO2001017562A1 (en) 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Osteogenesis promoting agents
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
CN1219753C (zh) 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4-碘苯氨基苯氧肟酸的氧合酯
CA2441492C (en) 2001-03-23 2011-08-09 Bayer Corporation Rho-kinase inhibitors
DK1370552T3 (da) 2001-03-23 2007-05-07 Bayer Pharmaceuticals Corp Rho-kinase-inhibitorer
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
US20050130144A1 (en) 2001-09-21 2005-06-16 Norio Nakatsuji Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
ES2305435T3 (es) 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibidores de la rho-quinasa.
WO2003062225A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
AU2003210405A1 (en) 2002-03-05 2003-09-16 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
HUE025767T2 (en) 2002-03-13 2016-05-30 Array Biopharma Inc N3-alkylated benzimidazole derivatives as MEK inhibitors
AU2003220935A1 (en) 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
EP1562935B1 (de) 2002-10-28 2006-09-06 Bayer HealthCare AG Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
MXPA05003431A (es) 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
JP2006517234A (ja) 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
EP1732581A4 (en) 2003-06-20 2008-06-04 Univ California San Diego POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
US7727762B2 (en) 2003-10-03 2010-06-01 Keiichi Fukuda Method of inducing the differentiation of stem cells into myocardial cells
JP4110324B2 (ja) 2003-10-15 2008-07-02 宇部興産株式会社 新規インダゾール誘導体
EP1673444A2 (en) 2003-10-16 2006-06-28 The University Court Of The University Of Edinburgh Control of es cell self-renewal and lineage specification, and medium therefor
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
AU2004291559B2 (en) 2003-11-19 2008-10-16 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
US20080275062A1 (en) 2004-01-30 2008-11-06 David Harold Drewry Chemical Compounds
EP1740601B1 (en) 2004-04-21 2012-12-05 The University of Chicago Myosin light chain kinase inhibitors and their use
KR20070083559A (ko) 2004-08-13 2007-08-24 더 유니버시티 오브 죠지아 리서치 파운데이션, 인코포레이티드 인간 배아 줄기세포에서의 자가재생 및 분화를 위한 조성물및 방법
WO2006026473A2 (en) 2004-08-25 2006-03-09 University Of Georgia Research Foundation, Inc. METHODS AND COMPOSITIONS UTILIZING MYC AND GSK3ß TO MANIPULATE THE PLURIPOTENCY OF EMBRYONIC STEM CELLS
WO2006088867A2 (en) 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
ES2405785T3 (es) 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
AU2006275479B2 (en) 2005-08-01 2012-11-29 Nupotential, Inc. Production of reprogrammed cells with restored potential
US20080242594A1 (en) 2005-09-08 2008-10-02 Mckay Ronald D G Methods for Promoting Stem Cell Proliferation and Survival
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
WO2007088651A1 (ja) 2006-02-01 2007-08-09 The University Of Tokyo TGF-βシグナル阻害剤と抗腫瘍剤の組み合せ使用
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
US9074180B2 (en) 2006-03-30 2015-07-07 The University Court Of The University Of Edinburgh Culture medium containing kinase inhibitors, and uses thereof
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
CA2650561C (en) 2006-05-02 2014-02-25 Wisconsin Alumni Research Foundation Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
JP2009542666A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション P53活性を増加させる置換ピペリジンおよびその使用
JP4960450B2 (ja) 2006-07-14 2012-06-27 ノバルティス アーゲー Alk−5阻害剤としてのピリミジン誘導体
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
CN101563449A (zh) 2006-09-22 2009-10-21 理化学研究所 干细胞培养基及干细胞培养方法
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
US7892830B2 (en) 2007-01-17 2011-02-22 Wisconsin Alumni Research Foundation Clonal culture of human pluripotent stem cells
US20100172883A1 (en) 2007-01-19 2010-07-08 Bruneau Benoit Gaetan Methods of generating cardiomyocytes
KR20090115142A (ko) 2007-01-30 2009-11-04 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 초기 중배엽 세포,내배엽 및 중배엽 계통의 생성에 유용한 중내배엽 세포의 안정한 집단 및 다능성 유주 세포(mmc)
KR20090122946A (ko) 2007-02-27 2009-12-01 주식회사 프로셀제약 줄기세포의 자가-재생을 촉진하고 분화를 억제하기 위한 세포투과성 nanog 및 oct4의 병합 용도
EP2131840B1 (en) 2007-03-07 2018-10-17 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
CN103555654B (zh) 2007-04-18 2016-04-20 哈达锡特医学研究服务及发展有限公司 干细胞衍生的视网膜色素上皮细胞
US7878210B2 (en) 2007-06-04 2011-02-01 Philip Morris Usa Inc. Cellulose acetate fiber modification
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
KR20160005142A (ko) 2007-06-29 2016-01-13 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 배아줄기세포 배양을 위한 자동화 방법 및 장치
US20120282229A1 (en) 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
JP6151879B2 (ja) 2007-08-31 2017-06-21 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 体細胞を再プログラミングすることにおけるwnt経路の刺激
CN101617043B (zh) 2007-10-31 2014-03-12 国立大学法人京都大学 核重编程方法
US20110151447A1 (en) 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
US20110033931A1 (en) 2007-11-29 2011-02-10 Children's Hospital Of Orange County De-differentiation of human cells
WO2009067756A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
EP2224940A1 (en) 2007-11-30 2010-09-08 Cytomatrix PTY LTD Methods of inducing pluripotency involving oct4 protein
SG188904A1 (en) 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
JP2011516042A (ja) 2008-03-17 2011-05-26 へルムホルツ・ツェントルム・ミュンヘン−ドイチェス・フォルシュングスツェントルム・ヒューア・ゲズントハイト・ウント・ウムヴェルト(ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング) 部位特異的組み換えを用いて無ベクター誘導多能性幹(iPS)細胞を作製するベクターおよびその方法
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
CA2697621C (en) 2008-07-30 2017-01-17 Kyoto University Method of efficiently establishing induced pluripotent stem cells
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
CA2907326A1 (en) 2008-11-04 2010-05-14 Chad Green Stem cell aggregate suspension compositions and methods for differentiation thereof
CA2745266C (en) 2008-12-03 2018-04-10 Yue Xu Stem cell cultures
EP3312269A1 (en) 2008-12-17 2018-04-25 The Scripps Research Institute Generation and maintenance of stem cells
WO2010102267A2 (en) 2009-03-06 2010-09-10 Ipierian, Inc. Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
CA2758003A1 (en) 2009-04-13 2010-10-21 The Regents Of The University Of California Methods and compositions for stem cell cultures
US20100303775A1 (en) 2009-05-27 2010-12-02 The Salk Institute For Biological Studies Generation of Genetically Corrected Disease-free Induced Pluripotent Stem Cells
WO2010137348A1 (en) 2009-05-29 2010-12-02 Keio University Method for selecting clone of induced pluripotent stem cells
US8524498B2 (en) 2009-05-29 2013-09-03 The General Hospital Corporation Methods and compositions for homologous recombination in human cells
CN103087991B (zh) * 2009-06-05 2018-06-12 富士胶片细胞动力公司 重编程t细胞和造血细胞的方法
AU2010279913B2 (en) 2009-08-07 2016-04-28 Kyoto University Method of efficiently establishing induced pluripotent stem cells
MX337982B (es) 2009-10-16 2016-03-30 Scripps Research Inst Induccion de celulas pluripotentes.
SI2494039T1 (sl) 2009-10-31 2020-03-31 Genesis Technologies Limited Postopek reprogramiranja celic in njihova uporaba
WO2011056971A2 (en) 2009-11-04 2011-05-12 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
EP2499236B1 (en) 2009-11-12 2020-01-01 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
JP5827220B2 (ja) * 2010-01-22 2015-12-02 国立大学法人京都大学 人工多能性幹細胞の樹立効率改善方法
WO2011103343A2 (en) 2010-02-17 2011-08-25 Biotime Inc. Methods for telomere length and genomic dna quality control analysis in pluripotent stem cells
CN102844428B (zh) 2010-03-05 2015-09-02 德克萨斯心脏研究所 Ets2和mesp1由成纤维细胞生成心脏祖细胞
EP3199623B1 (en) 2010-03-31 2021-07-28 The Scripps Research Institute Reprogramming cells
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
JPWO2011158852A1 (ja) 2010-06-15 2013-08-19 国立大学法人 東京大学 誘導型多能性幹細胞の製造方法
ES2670842T3 (es) 2010-06-15 2018-06-01 Cellular Dynamics International, Inc. Generación de células madre pluripotentes inducidas a partir de pequeños volúmenes de sangre periférica
JP5936218B2 (ja) 2010-08-04 2016-06-22 セルラー ダイナミクス インターナショナル, インコーポレイテッド 不死化b細胞のリプログラミング
CA2822638C (en) 2010-12-22 2021-02-16 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
WO2013070852A2 (en) * 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
AU2012347534B2 (en) 2011-12-08 2018-01-25 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
JP6164746B2 (ja) 2012-05-22 2017-07-19 国立大学法人 東京大学 抗原特異的t細胞の製造方法
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation
AU2015227184B2 (en) * 2014-03-04 2021-05-20 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
JP7263005B2 (ja) 2015-10-16 2023-04-24 フェイト セラピューティクス,インコーポレイテッド 基底状態の多能性の誘導及び維持に関するプラットフォーム
PT3371314T (pt) 2015-11-04 2023-08-31 Fate Therapeutics Inc Modificação genómica de células pluripotentes

Also Published As

Publication number Publication date
JP7170600B2 (ja) 2022-11-14
KR20210111884A (ko) 2021-09-13
KR20160130260A (ko) 2016-11-10
JP2019187454A (ja) 2019-10-31
AU2015227184A1 (en) 2016-09-15
JP2022082668A (ja) 2022-06-02
KR102460549B1 (ko) 2022-10-28
EP3114214A1 (en) 2017-01-11
US20220228125A1 (en) 2022-07-21
JP2018086018A (ja) 2018-06-07
KR102340553B1 (ko) 2021-12-21
KR102670874B1 (ko) 2024-05-31
JP6722108B2 (ja) 2020-07-15
US11268069B2 (en) 2022-03-08
AU2021218109A1 (en) 2021-09-09
AU2021218109B2 (en) 2024-05-02
CA2941004A1 (en) 2015-09-11
ES2966757T3 (es) 2024-04-24
EP3114214B1 (en) 2023-11-01
CN106414721A (zh) 2017-02-15
JP2023126627A (ja) 2023-09-07
SG11201606934SA (en) 2016-09-29
AU2015227184B2 (en) 2021-05-20
SG10201807292YA (en) 2018-09-27
EP3604499A1 (en) 2020-02-05
US20170073643A1 (en) 2017-03-16
WO2015134652A1 (en) 2015-09-11
EP3114214A4 (en) 2017-08-09
KR20220147728A (ko) 2022-11-03
JP2021000107A (ja) 2021-01-07
EP3805369A1 (en) 2021-04-14
JP2017506904A (ja) 2017-03-16

Similar Documents

Publication Publication Date Title
SG11201606934SA (en) Improved reprogramming methods and cell culture platforms
EP3472301C0 (en) CELL CULTURE DEVICE AND METHODS
LU92752B1 (en) Cell culture apparatus and culture methods using same
SG11201703493SA (en) Cell culture insert
SG11201609916RA (en) Culture method and cell mass
HK1255101A1 (zh) 用於得到調節性t細胞的方法及其用途
SG11201705853VA (en) Cell culture device and cell culture method
EP3124589A4 (en) Cell culture method and cell culture system
GB201611982D0 (en) Cell culture
EP3115450A4 (en) Cell culture method and cell culture device
EP3196292A4 (en) Cell culture apparatus and method
HK1247232A1 (zh) 細胞和組織培養容器
EP3107996A4 (en) Tscm cells and methods for use
SG11202004935UA (en) Cell culture methods
PL3224341T3 (pl) Materiały i sposoby do przedłużania pożywki do hodowli komórkowej
SI3766582T1 (sl) Celična kultura
SG11201702897WA (en) Cell culture bag and cell culture method
IL270880A (en) Cell culture methods
EP3235902A4 (en) Cell culture method and cell culture device
PL3132020T3 (pl) Naczynie do hodowli komórek i jego zastosowanie
EP3192295A4 (en) Method and arrangement for cell combination
PL3287521T3 (pl) Hodowla komórkowa
GB201418980D0 (en) Cell assay kit and method
TWI563082B (en) Cell culture device
SG10202010002RA (en) Cell culture